Harvard Bioscience (HBIO) EBITDA (2010 - 2026)
Harvard Bioscience (HBIO) EBITDA from Jun 30, 2010 to Mar 31, 2026. The TTM Harvard Bioscience (HBIO) EBITDA is $1.66M. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EBITDA
Quarterly EBITDA
Harvard Bioscience (HBIO) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 3 Years TTM | -17.25% |
| 5 Years TTM | -20.26% |
| 10 Years TTM | +5.41% |
| All Time TTM | -8.56% |
Annual EBITDA change of Harvard Bioscience (HBIO)
| Year | EBITDA | Change |
|---|---|---|
| 2026 | -$730K | -98.44% |
| 2025 | -$47M | +945.54% |
| 2024 | -$4.48M | -232.94% |
| 2023 | $3.37M | -161.50% |
| 2022 | -$5.48M | -242.34% |
| 2021 | $3.85M | +79.91% |
| 2020 | $2.14M | -40.88% |
| 2019 | $3.62M | +6.16% |
| 2018 | $3.41M | +401.47% |
| 2017 | $680K | -146.58% |
| 2016 | -$1.46M | -4966.67% |
| 2015 | $30K | -99.62% |
| 2014 | $7.87M | +177.11% |
| 2013 | $2.84M | -76.41% |
| 2012 | $12M | -5.42% |
| 2011 | $13M | -9.97% |
| 2010 | $14M | +52.70% |
| 2009 | $9.26M | N/A |
Comparison Harvard Bioscience (HBIO) five years EBITDA CAGR with competitors
Harvard Bioscience (HBIO) five years EBITDA CAGR is -20.33%.
| Ticker | Name | five years EBITDA CAGR | Upside |
|---|---|---|---|
| POCI | Precision Optics Corp Inc | 111.37% | -647.75% |
| NYXH | Nyxoah SA | 45.05% | -321.57% |
| GCTK | GlucoTrack Inc | 38.94% | -291.50% |
| STXS | Stereotaxis Inc | 28.84% | -241.84% |
| RGNT | Regentis Biomaterials Ltd | 26.85% | -232.04% |
| MMSI | Merit Medical Systems Inc | 24.73% | -221.63% |
| BLFS | Biolife Solutions Inc | 22.17% | -209.02% |
| ISRG | Intuitive Surgical Inc | 21.90% | -207.73% |
| ZTEK | Zentek Ltd | 21.48% | -205.64% |
| COO | Cooper Companies Inc | 17.51% | -186.14% |
| RGEN | Repligen Corp | 15.86% | -177.99% |
| RMD | Resmed Inc | 15.14% | -174.49% |
| LMAT | Lemaitre Vascular Inc | 14.82% | -172.90% |
| PDEX | Pro-Dex Inc (co) | 13.53% | -166.53% |
| ALC | Alcon Inc | 12.44% | -161.16% |
| MBOT | Microbot Medical Inc | 11.58% | -156.97% |
| STVN | Stevanato Group Spa | 9.05% | -144.53% |
| NXGL | Nexgel Inc | 7.05% | -134.66% |
| ATR | Aptargroup Inc | 6.79% | -133.41% |
| PLSE | Pulse Biosciences Inc | 6.69% | -132.92% |
| WST | West Pharmaceutical Services Inc | 6.51% | -132.02% |
| ICUI | ICU Medical Inc | 5.71% | -128.07% |
| ALGN | Align Technology Inc | 4.82% | -123.73% |
| EKSO | Ekso Bionics Holdings Inc | 4.60% | -122.61% |
| BDX | Becton Dickinson & Company | 4.54% | -122.33% |
| NVST | Envista Holdings Corp | 4.52% | -122.24% |